SyntekaBio,Inc. Logo

SyntekaBio,Inc.

An AI-driven drug discovery company using supercomputing to accelerate development.

226330 | KO

Overview

Corporate Details

ISIN(s):
KR7226330009
LEI:
Country:
South Korea
Address:
대전광역시 유성구 국제과학17로 18 -, 대전광역시

Description

SyntekaBio is an AI-driven drug discovery company that utilizes its proprietary supercomputing infrastructure, the AI Bio-Supercom Center, to accelerate pharmaceutical development. The company's core technology, the DeepMatcher® platform, underpins a suite of services for discovering small molecules, antibodies, and neoantigens for personalized cancer vaccines. A key offering is LaunchPad, a factory-like system that continuously generates a stream of 'off-the-shelf' drug candidates for numerous disease targets, aiming to expedite the path to IND-enabling studies. SyntekaBio delivers its solutions through comprehensive discovery partnerships and a modular, cloud-based Software as a Service (SaaS) platform, STB CLOUD, providing researchers with automated tools for drug development and genomics analysis.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2025-12-29 00:00
주식등의대량보유상황보고서(일반)
Korean HTML 155.2 KB
2025-12-29 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 26.5 KB
2025-12-29 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean HTML 25.6 KB
2025-12-29 00:00
전환사채(해외전환사채포함)발행후만기전사채취득
Korean HTML 10.3 KB
2025-12-24 00:00
[기재정정]단일판매ㆍ공급계약체결
Korean HTML 13.9 KB
2025-12-24 00:00
[기재정정]단일판매ㆍ공급계약체결
Korean HTML 14.0 KB
2025-12-22 00:00
최대주주변경을수반하는주식담보제공계약해제ㆍ취소등
Korean HTML 29.8 KB
2025-12-19 00:00
증권발행결과(자율공시)
Korean HTML 8.2 KB
2025-12-19 00:00
증권발행실적보고서
Korean HTML 72.5 KB
2025-12-18 00:00
유상증자또는주식관련사채등의청약결과(자율공시)
Korean HTML 12.2 KB
2025-12-17 00:00
주식등의대량보유상황보고서(일반)
Korean HTML 126.5 KB
2025-12-17 00:00
단일판매ㆍ공급계약체결
Korean HTML 9.4 KB
2025-12-16 00:00
투자판단관련주요경영사항 (Ab-ARS™플랫폼으로 발굴한 항암 및 면역질환 항체 후보물질 기술이전)
Korean HTML 11.8 KB
2025-09-19 00:00
주식등의대량보유상황보고서(약식)
Korean HTML 64.1 KB
2025-09-15 00:00
주식등의대량보유상황보고서(일반)
Korean HTML 100.9 KB

Automate Your Workflow. Get a real-time feed of all SyntekaBio,Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for SyntekaBio,Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for SyntekaBio,Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Alpha Tau Medical Ltd. Logo
Clinical-stage oncology firm developing alpha radiation therapy for solid tumors.
United States of America
DRTS
Alteogen Inc. Logo
Biopharmaceutical firm developing biologics with proprietary drug delivery technologies.
South Korea
196170
AlzeCure Pharma Logo
Develops therapies for severe diseases, focusing on Alzheimer's and pain.
Sweden
ALZCUR
ANAPTYSBIO, INC Logo
Clinical-stage biotech developing immunology therapeutics for inflammatory diseases.
United States of America
ANAB
AngioLab, Inc. Logo
Develops angiogenesis inhibitors for pharmaceuticals and health functional foods.
South Korea
251280
Anixa Biosciences Inc Logo
A clinical-stage biotech developing therapies and vaccines to treat and prevent cancer.
United States of America
ANIX
Annovis Bio, Inc. Logo
A clinical-stage drug platform company developing therapies for neurodegenerative diseases.
United States of America
ANVS
Develops and manufactures DNA-based technologies for genetic medicine and diagnostics.
United States of America
APDN
Aprea Therapeutics, Inc. Logo
Clinical-stage biopharma developing cancer therapeutics via synthetic lethality.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases, oncology, and rare diseases.
South Korea
397030

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.